Altimmune Shares Tumble After Goldman Sachs Issues Sell Rating

Altimmune shares are trading lower after Goldman Sachs initiated coverage with a Sell rating and a $1 price target, citing challenges in differentiation and clinical program execution for its lead candidate, pemvidutide.